Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) Director Jennifer Doudna sold 2,673 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $55.00, for a total value of $147,015.00. Following the transaction, the director directly owned 25,942 shares in the company, valued at $1,426,810. This trade represents a 9.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Tempus AI Stock Down 0.7%
TEM opened at $57.93 on Wednesday. Tempus AI, Inc. has a 12 month low of $41.73 and a 12 month high of $104.32. The company has a current ratio of 3.31, a quick ratio of 3.15 and a debt-to-equity ratio of 2.96. The business’s 50-day moving average price is $50.19 and its 200-day moving average price is $54.68. The company has a market cap of $10.40 billion, a P/E ratio of -33.68 and a beta of 3.62.
Tempus AI (NASDAQ:TEM – Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.08. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The company had revenue of $348.12 million during the quarter, compared to analysts’ expectations of $345.44 million. During the same period in the prior year, the business posted ($0.24) EPS. Tempus AI’s quarterly revenue was up 36.1% compared to the same quarter last year. On average, equities analysts expect that Tempus AI, Inc. will post -1.35 EPS for the current year.
Hedge Funds Weigh In On Tempus AI
Key Stories Impacting Tempus AI
Here are the key news stories impacting Tempus AI this week:
- Positive Sentiment: One analyst-style article argued Tempus AI remains attractive because of strong diagnostics momentum, expanding AI platform adoption, and recent FDA-related product expansion that could broaden its addressable market. Tempus AI: Buy On Diagnostics Momentum And AI Platform Expansion
- Positive Sentiment: Another article highlighted that Tempus AI’s recent pullback may have created a potential buying opportunity, suggesting some investors see value after the decline. Tempus AI stock faces a make-or-break moment after its recent pullback
- Neutral Sentiment: Konica Minolta completed the sale of Tempus shares it received in a prior transaction. This is not a direct operating update, but it removes a potential overhang from an outside holder. Konica Minolta Completes Sale of Tempus Shares to Bolster Balance Sheet
- Neutral Sentiment: Tempus also had a financial review and comparison coverage piece, but it did not include a major new company-specific catalyst. Financial Review: Tempus AI (NASDAQ:TEM) & Nyxoah (NASDAQ:NYXH)
- Negative Sentiment: Biovica said it is refocusing its U.S. commercial strategy and terminating its agreement with Tempus AI, which could signal a lost partnership or reduced commercial opportunity. Biovica Refocuses US Commercial Strategy and Terminates Agreement with Tempus AI
- Negative Sentiment: Tempus disclosed insider selling by CFO James William Rogers and Director Jennifer A. Doudna, which can weigh on investor sentiment even though both sales were made under pre-arranged trading plans. Tempus AI (NASDAQ:TEM) CFO James William Rogers Sells 11,529 Shares of Stock Tempus AI (NASDAQ:TEM) Director Sells 2,673 Shares of Stock
Wall Street Analysts Forecast Growth
A number of equities research analysts recently commented on the stock. Wolfe Research began coverage on shares of Tempus AI in a report on Tuesday, June 2nd. They set a “peer perform” rating for the company. HC Wainwright cut their price target on shares of Tempus AI from $95.00 to $64.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Needham & Company LLC restated a “buy” rating and issued a $75.00 price objective on shares of Tempus AI in a research report on Monday, June 1st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tempus AI in a research note on Wednesday, June 17th. Finally, Wall Street Zen upgraded shares of Tempus AI from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $68.54.
Check Out Our Latest Stock Analysis on TEM
Tempus AI Company Profile
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
See Also
- Five stocks we like better than Tempus AI
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.
